FR2858769B1 - Utilisation d'un peptide comme principe actif amincissant - Google Patents

Utilisation d'un peptide comme principe actif amincissant

Info

Publication number
FR2858769B1
FR2858769B1 FR0309889A FR0309889A FR2858769B1 FR 2858769 B1 FR2858769 B1 FR 2858769B1 FR 0309889 A FR0309889 A FR 0309889A FR 0309889 A FR0309889 A FR 0309889A FR 2858769 B1 FR2858769 B1 FR 2858769B1
Authority
FR
France
Prior art keywords
peptide
active ingredient
slimming active
slimming
ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0309889A
Other languages
English (en)
Other versions
FR2858769A1 (fr
Inventor
Farra Claude Dal
Nouha Domloge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vincience SA
Original Assignee
Societe dExtraction des Principes Actifs SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0309889A priority Critical patent/FR2858769B1/fr
Application filed by Societe dExtraction des Principes Actifs SA filed Critical Societe dExtraction des Principes Actifs SA
Priority to PCT/FR2003/003280 priority patent/WO2004043482A1/fr
Priority to DE60336756T priority patent/DE60336756D1/de
Priority to EP03767892A priority patent/EP1575605B1/fr
Priority to AT03767892T priority patent/ATE505199T1/de
Priority to AU2003292326A priority patent/AU2003292326A1/en
Priority to US10/534,355 priority patent/US7504092B2/en
Publication of FR2858769A1 publication Critical patent/FR2858769A1/fr
Application granted granted Critical
Publication of FR2858769B1 publication Critical patent/FR2858769B1/fr
Priority to US12/071,002 priority patent/US7674451B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
FR0309889A 2002-11-08 2003-08-13 Utilisation d'un peptide comme principe actif amincissant Expired - Fee Related FR2858769B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR0309889A FR2858769B1 (fr) 2003-08-13 2003-08-13 Utilisation d'un peptide comme principe actif amincissant
DE60336756T DE60336756D1 (de) 2002-11-08 2003-11-04 Pharmazeutische, kosmetische oder therapeutische zusammensetzungen enthaltend peptide mit dem motiv arg-gly-ser
EP03767892A EP1575605B1 (fr) 2002-11-08 2003-11-04 Composition cosmetique ou pharmaceutique comprenant des peptides possedant le motif arg-gly-ser
AT03767892T ATE505199T1 (de) 2002-11-08 2003-11-04 Pharmazeutische, kosmetische oder therapeutische zusammensetzungen enthaltend peptide mit dem motiv arg-gly-ser
PCT/FR2003/003280 WO2004043482A1 (fr) 2002-11-08 2003-11-04 Composition cosmetique ou pharmaceutique comprenant des peptides, possedant le motif arg-gly-ser
AU2003292326A AU2003292326A1 (en) 2002-11-08 2003-11-04 Cosmetic or pharmaceutical composition comprising peptides with the sequence arg-gly-ser
US10/534,355 US7504092B2 (en) 2002-11-08 2003-11-04 Cosmetic or pharmaceutical composition comprising peptides, uses and treatment processes
US12/071,002 US7674451B2 (en) 2002-11-08 2008-02-14 Cosmetic or pharmaceutical composition comprising peptides, uses and treatment processes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0309889A FR2858769B1 (fr) 2003-08-13 2003-08-13 Utilisation d'un peptide comme principe actif amincissant

Publications (2)

Publication Number Publication Date
FR2858769A1 FR2858769A1 (fr) 2005-02-18
FR2858769B1 true FR2858769B1 (fr) 2006-02-10

Family

ID=34112744

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0309889A Expired - Fee Related FR2858769B1 (fr) 2002-11-08 2003-08-13 Utilisation d'un peptide comme principe actif amincissant

Country Status (1)

Country Link
FR (1) FR2858769B1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2900826B1 (fr) 2006-05-12 2008-08-15 Soc Extraction Principes Actif Utilisation de peptides en tant que principes actifs amincissants.
FR2999080B1 (fr) 2012-12-11 2015-03-20 Isp Investments Inc Utilisation cosmetique de l'association d'un extrait de de germe de caroube et de cafeine en tant qu'agent actif amincissant
FR2999079B1 (fr) 2012-12-11 2015-04-24 Isp Investments Inc Utilisation cosmetique d'un extrait de germe de caroube en tant qu'agent actif amincissant
EP3509706B1 (fr) 2016-09-07 2021-11-03 ISP Investments LLC Procédé permettant d'augmenter la lipolyse à l'aide d'une composition comprenant un extrait bioactif de nelumbo nucifera (lotus)
FR3114241A1 (fr) 2020-09-18 2022-03-25 C F E B Sisley Compositions cosmétiques amincissantes contenant un ou plusieurs limonoïdes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5427954A (en) * 1992-04-29 1995-06-27 Shriner's Hospitals For Crippled Children Compositions and methods for detection and treatment of human osteoarthritis
FR2735687B1 (fr) * 1995-06-21 1997-08-14 Sederma Sa Nouvelles compositions cosmetiques amincissantes
FR2761602B1 (fr) * 1997-04-02 1999-05-14 Sederma Sa Compositions cosmetiques amincissantes
US20050181474A1 (en) * 2002-01-30 2005-08-18 Frank J. Giordano Transport peptides and uses therefor

Also Published As

Publication number Publication date
FR2858769A1 (fr) 2005-02-18

Similar Documents

Publication Publication Date Title
DE50309032D1 (de) Fungizide wirkstoffkombinationen
DE50309693D1 (de) Fungizide wirkstoffkombination
NO2014021I1 (no) Bedaquiline eller et farmasøytisk akseptabelt syre- eller baseaddisjonssalt derav
CY2009013I2 (el) Νεα χρηση μιας ενωσης πεπτιδικης κατηγοριας για τη θεραπεια του μη νευροπαθους φλεγμονωδους πονου
FR12C0019I2 (fr) O-cyclopropyle-carboxanilides et leur utilisation comme fongicides
ATE411302T1 (de) Thiazolidin-4-ones um hyak3 proteinen zu hemmen
FR2887447B1 (fr) Utilisation d'un peptide comme principe actif amincissant
ATE488224T1 (de) Aerosol-formulierungen von diisobutyryl apomorphine
ATE336954T1 (de) Marknagel
FR2908045B1 (fr) Utilisation anti-pelliculaire d'un principe actif riche en tannis hydrolysables
DE50213466D1 (de) Fungizide wirkstoffkombinationen
FR2851460B1 (fr) Utilisation de n-lauroyl aminoacides comme actif cosmetique et pharmaceutique amincissant
DE50313212D1 (de) Blausäure aus formamid
FR2858769B1 (fr) Utilisation d'un peptide comme principe actif amincissant
TW510160U (en) Structure of clippers for gardening use
FR2810323B1 (fr) Utilisation cosmetique d'un lipopeptide
FR2883472B1 (fr) Utilisation d'un acide chlorogenique en tant qu'un actif amincissant
ITMI20020161A1 (it) Filtro attivo
DE60333439D1 (de) Herstellung von olefinen
FR2866562B1 (fr) Utilisation d'un tetrapolymere acrylique comme agent tenseur de la peau.
FR2851461B1 (fr) Utilisation de n-octanoyl aminoacides comme actif cosmetique et pharmaceutique amincissant
EE200300434A (et) Farmatseutiliselt toimivate ühendite kasutamine
FI20020360A0 (fi) Biologisesti aktiivisen tuotteen uusi käyttö
FR2849379B1 (fr) Encapsulation d'actifs liposolubles
DE60336549D1 (de) Hepatoprotektor aktivität von 2'-p-hydroxybenzoylmussaenosidsäure

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

ST Notification of lapse

Effective date: 20200406